<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01185132</url>
  </required_header>
  <id_info>
    <org_study_id>2009-APBI</org_study_id>
    <secondary_id>WIRB #20091193</secondary_id>
    <nct_id>NCT01185132</nct_id>
  </id_info>
  <brief_title>Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy</brief_title>
  <acronym>2009-APBI</acronym>
  <official_title>A Phase III Randomized Study Comparing Intensity Modulated Planning Versus 3-Dimensional Planning for Accelerated Partial Breast Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rocky Mountain Cancer Centers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rocky Mountain Cancer Centers</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the setting of radiotherapy as part of breast-conservation therapy for patients with early
      stage breast cancer, the novel planning and delivery method of intensity modulated
      radiotherapy is an effective and safe alternative to the commonly-used standard 3D-conformal
      external beam radiotherapy, spares more normal breast and lung tissue, and may lead to
      improved clinical outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">July 2028</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of breast pain after Accelerated Partial Breast Radiotherapy (APBI)</measure>
    <time_frame>5 years</time_frame>
    <description>Assessment by both treating investigators and by subjective patient outcomes questionnaires filled out at each follow-up visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of chest wall pain after Accelerated Partial Breast Radiotherapy (APBI)</measure>
    <time_frame>2-5 years</time_frame>
    <description>Assessment by both treating investigators and by subjective patient outcomes questionnaires filled out at each follow-up visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dosimetric comparison</measure>
    <time_frame>5-10 days</time_frame>
    <description>Comparison of treatment plans and actual doses received between comparable patients treated with 3D-CRT and IMRT with regard to treatment target and normal tissue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute skin reactions</measure>
    <time_frame>6 months</time_frame>
    <description>Radiation-induced dermatitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cosmetic outcomes after APBI</measure>
    <time_frame>2-5 years</time_frame>
    <description>Assesed by both treating investigators and subjective patient questionnaires filled out at each follow-up visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ipsilateral breast event</measure>
    <time_frame>5-15 years</time_frame>
    <description>Track occurrence and patterns of local treatment failures or new primaries within the treated breast (efficacy outcome measure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cause specific survival</measure>
    <time_frame>5-15 years</time_frame>
    <description>Track survival status and the specific cause(s) of death if applicable for study participants (efficacy outcome measure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>5-15 years</time_frame>
    <description>Track breast-cancer free survival status of study participants (efficacy outcome measure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5-15 years</time_frame>
    <description>Track the overall survival status of all study participants (efficacy outcome measure)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">660</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>IMRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intensity modulated radiotherapy, 38.5 Gy, 10 fractions over 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3D-CRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Three dimensional conformal external radiotherapy, 38.5 Gy, 10 fractions over 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>accelerated partial breast irradiation - 3D-conformal planning</intervention_name>
    <description>38.5 Gy, 10 fractions over 5 days</description>
    <arm_group_label>3D-CRT</arm_group_label>
    <other_name>APBI</other_name>
    <other_name>EBRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>accelerated partial breast irradiation - IMRT planning</intervention_name>
    <description>38.5 Gy, 10 fractions over 5 days</description>
    <arm_group_label>IMRT</arm_group_label>
    <other_name>APBI</other_name>
    <other_name>EBRT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed disease (AJC Classification): Tis, T1, T2 (≤ 3.0 cm), N0, M0.

          -  Microscopic multifocal disease is only allowed when the entire span of identified
             disease measures 3.0 cm or less.

          -  Negative surgical margins ( ≥ 0.2 cm) after final surgery.

          -  Subjects with infiltrating lobular histologies or high nuclear grade DCIS will be
             required to have breast MRI scanning as part of the initial staging to verify
             localized disease.

          -  Subjects with DCIS will be included in the study only if they had an MRI prior to
             lumpectomy.

          -  Findings on MRI scanning revealing relevant suspicion of disease outside of planned
             lumpectomy volume should be further evaluated by ultrasound and, if necessary biopsy,
             to exclude multicentric/multifocal disease.

          -  Subjects with malignant calcifications on mammography will be required to have repeat
             mammography after surgery to ensure removal of all malignant calcifications.

          -  Willing to complete additional screening requirements and meet eligibility criteria as
             defined in protocol Sec. 4.4.

          -  Successful placement of fiducial markers for IGRT requiring nonmigrating fiducials.

          -  PTV to ipsilateral breast ratio (IBR) ≤ 25 %.

          -  Radiotherapy anticipated to begin within 10 weeks of lumpectomy or re-excision of
             margins.

        Exclusion Criteria:

          -  Pregnancy or breast-feeding.

          -  Have collagen-vascular disease.

          -  Inadequate surgical margins ( &lt; 0.2 cm) after final surgery.

          -  Subjects with persistent malignant/suspicious micro-calcifications.

          -  Gross multifocal disease and microscopic disease greater than 3.0 cm.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Leonard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rocky Mountain Cancer Centers</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rachel Lei, BS</last_name>
    <phone>303-418-7607</phone>
    <email>rachel.lei@usoncology.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charles Leonard, MD</last_name>
    <phone>303-730-4700</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers - Aurora</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dennis Carter, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>William Daniel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kathryn Howell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers - Boulder</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrew Antell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meera Patel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ralph Wright, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers - Lakewood</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ralph Wright, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles Leonard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers - Littleton</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Charles Leonard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kathryn Howell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers - Thornton</name>
      <address>
        <city>Thornton</city>
        <state>Colorado</state>
        <zip>80260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Robert LaPorte, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Chin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2010</study_first_submitted>
  <study_first_submitted_qc>August 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2010</study_first_posted>
  <last_update_submitted>June 24, 2014</last_update_submitted>
  <last_update_submitted_qc>June 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast-conservation</keyword>
  <keyword>adjuvant radiotherapy</keyword>
  <keyword>breast cancer</keyword>
  <keyword>early-stage breast cancer</keyword>
  <keyword>DCIS</keyword>
  <keyword>lumpectomy</keyword>
  <keyword>accelerated partial breast irradiation</keyword>
  <keyword>APBI</keyword>
  <keyword>three dimensional conformal external radiotherapy</keyword>
  <keyword>intensity modulated radiotherapy</keyword>
  <keyword>3D CRT</keyword>
  <keyword>IMRT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

